Citations

Showing 10 of 108162 citations.

Clostridioides difficile infection: a comprehensive review for primary providers
Cortés, Pedro , Bi, Yan , Valery, Jose R. , Cooper, Jane H., Stancampiano, Fernando, Harris, Dana M. , Cortés, Pedro , Stancampiano, Fernando F.

Mayo Clinic

Romanian Journal of Internal Medicine | April 6, 2021 | Volume: 59 | Issue: 3 | Pages: 262-269

10.2478/rjim-2021-0010 | PMID 33713592 Get It

Abstract Clostridioides difficile infection (CDI) is an issue of great concern due to its rising incidence, recurrence, morbidity and impact on healthcare spending. Treatment guidelines have changed in the last few years, and new therapies are being considered. This is a practical review for the primary care practitioner of the latest guidelines for CDI diagnosis, treatment, and emerging therapies.
Hepatorenal syndrome: pathophysiology and evidence-based management update
Hasan, Irtiza , Rashid, Tasnuva, Chirilă, Răzvan M. , Ghali, Peter , Wadei, Hani M. , Wadei, Hani M

Mayo Clinic

Romanian Journal of Internal Medicine | April 6, 2021 | Volume: 59 | Issue: 3 | Pages: 227-261

10.2478/rjim-2021-0006 | PMID 33544554 Get It

Abstract Hepatorenal syndrome (HRS) is a functional renal failure that develops in patients with advanced hepatic cirrhosis with ascites and in those with fulminant hepatic failure. The prevalence of HRS varies among studies but in general it is the third most common cause of acute kidney injury (AKI) in cirrhotic patients after pre-renal azotemia and acute tubular necrosis. HRS carries a grim prognosis with a mortality rate approaching 90% three months after disease diagnosis. Fortunately, different strategies have been proven to be successful in preventing HRS. Although treatment options are available, they are not universally effective in restoring renal function but they might prolong survival long enough for liver transplantation, which is the ultimate treatment. Much has been learned in the last two decades regarding the pathophysiology and management of this disease which lead to notable evolution in the HRS definition and better understanding on how best to manage HRS patients. In the current review, we will summarize the recent advancement in epidemiology, pathophysiology, and management of HRS.
The low excretor phenotype of glutaric acidemia type I is a source of false negative newborn screening results and challenging diagnoses
Guenzel, Adam J. , Scott, Anna I. , Lam, Christina , Chang, Irene J. , Thies, Jenny , Pichurin, Pavel N. , Laxen, William , Raymond, Kimiyo , Gavrilov, Dimitar K. , Oglesbee, Devin , Rinaldo, Piero, Matern, Dietrich , Tortorelli, Silvia , Oglesbee, Devin , Thies, Jenny M , Hall, Patricia , Ferreira, Carlos R

Mayo Clinic

JIMD Reports | April 6, 2021 | Volume: 60 | Issue: 1 | Pages: 67-74

10.1002/jmd2.12217 | PMID 34258142 Get It

AbstractBackgroundGlutaric acidemia type I (GA1) is an organic acidemia that is often unrecognized in the newborn period until patients suffer an acute encephalopathic crisis, which can be mistaken for nonaccidental trauma. Presymptomatic identification of GA1 patients is possible by newborn screening (NBS). However, the biochemical “low‐excretor” (LE) phenotype with nearly normal levels of disease metabolites can be overlooked, which may result in untreated disease and irreversible neurological sequelae. The LE phenotype is also a potential source of false negative (FN) NBS results that merits further investigation.MethodsSamples from six LE GA1 patients were analyzed by biochemical and molecular methods and newborn screen outcomes were retrospectively investigated.ResultsFive LE GA1 patients were identified that had normal NBS results and three of these presented clinically with GA1 symptoms. One additional symptomatic patient was identified who did not undergo screening. Semiquantitative urine organic acid analysis was consistent with a GA1 diagnosis in two (33%) of the six patients, while plasma glutarylcarnitine was elevated in four (67%) of the six and urine glutarylcarnitine was elevated in four (80%) of five patients. Five GCDH variants were identified in these patients; three of which have not been previously linked to the biochemical LE phenotype.ConclusionsThe data presented here raise awareness of potential FN NBS results for LE GA1 patients. The LE phenotype is not protective against adverse clinical outcomes, and the possibility of FN NBS results calls for high vigilance amongst clinicians, even in the setting of a normal NBS result.
Primary Outcome Evaluation of a Next-Generation Left Atrial Appendage Closure Device
Kar, Saibal , Doshi, Shephal K. , Sadhu, Ashish, Horton, Rodney , Osorio, José , Stone, James, Shah, Manish H. , Dukkipati, Srinivas R. , Adler, Stuart W., Kim, Jamie , Wazni, Oussama M. , Price, Mathew J., Holmes, David R. , Shipley, Robert D., Gordon, Nicole, Allocco, Dominic J. , Investigators, On behalf of the PINNACLE FLX, Kar, Saibal , Ellis, Christopher R. , Nair, Devi G , Asch, Federico M. , Reddy, Vivek Y. , Investigators, On behalf of the PINNACLE FLX

Mayo Clinic

Circulation | April 6, 2021 | Volume: 143 | Issue: 18 | Pages: 1754-1762

10.1161/circulationaha.120.050117 | PMID 33820423 Get It

Background: Left atrial appendage (LAA) occlusion provides an alternative to oral anticoagulation for thromboembolic risk reduction in patients with nonvalvular atrial fibrillation. Since regulatory approval in 2015, the WATCHMAN device has been the only LAA closure device available for clinical use in the United States. The PINNACLE FLX study (Protection Against Embolism for Nonvalvular AF Patients: Investigational Device Evaluation of the Watchman FLX LAA Closure Technology) evaluated the safety and effectiveness of the next-generation WATCHMAN FLX LAA closure device in patients with nonvalvular atrial fibrillation in whom oral anticoagulation is indicated, but who have an appropriate rationale to seek a nonpharmaceutical alternative. Methods: This was a prospective, nonrandomized, multicenter US Food and Drug Administration study. The primary safety end point was the occurrence of one of the following events within 7 days after the procedure or by hospital discharge, whichever was later: death, ischemic stroke, systemic embolism, or device- or procedure-related events requiring cardiac surgery. The primary effectiveness end point was the incidence of effective LAA closure (peri-device flow ≤5 mm), as assessed by the echocardiography core laboratory at 12-month follow-up. Results: A total of 400 patients were enrolled. The mean age was 73.8±8.6 years and the mean CHA 2 DS 2 -VASc score was 4.2±1.5. The incidence of the primary safety end point was 0.5% with a 1-sided 95% upper CI of 1.6%, meeting the performance goal of 4.2% ( P <0.0001). The incidence of the primary effectiveness end point was 100%, with a 1-sided 95% lower CI of 99.1%, again meeting the performance goal of 97.0% ( P <0.0001). Device-related thrombus was reported in 7 patients, no patients experienced pericardial effusion requiring open cardiac surgery, and there were no device embolizations. Conclusions: LAA closure with this next-generation LAA closure device was associated with a low incidence of adverse events and a high incidence of anatomic closure. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT02702271.
Degenerative Cervical Myelopathy Presenting with Partial Brown Séquard Syndrome
Joseph, Amira , Moman, Rajat N. , Hunt, Terry L. , Hunt, Terry, Moman, Rajat

Mayo Clinic

Pain Medicine | April 5, 2021 | Volume: 23 | Issue: 1 | Pages: 213-217

10.1093/pm/pnab132 | PMID 33825895 Get It

Stability and Validation of a High-Throughput LC-MS/MS Method for the Quantification of Cefepime, Meropenem, and Piperacillin and Tazobactam in Serum
Bjergum, Matthew W., Frazee, Erin N. , Scheetz, Marc H. , Jannetto, Paul J. , Scheetz, Marc H , Rule, Andrew D.

Mayo Clinic

The Journal of Applied Laboratory Medicine | April 5, 2021 | Volume: 6 | Issue: 5 | Pages: 1202-1212

10.1093/jalm/jfab036 | PMID 34086904 Get It

Abstract Background The class of antibiotics known as β-lactams are a commonly used due to their effectiveness and safety. Therapeutic drug monitoring has been proposed but requires an accurate assay along with well-characterized preanalytic stability, as β-lactams are known to be relatively unstable. Methods A high-throughput LC-MS/MS assay validation and stability study was performed for cefepime, meropenem, and piperacillin and tazobactam in serum. Patient samples, standards, and QCs were crashed with acetonitrile containing internal standard. Following centrifugation, an aliquot of the supernatant was diluted with clinical laboratory reagent water and analyzed by LC-MS/MS. Results The assay showed linearity between 0.5 and 60 µg/mL for each analyte. The intra- and interassay reproducibility at 3 different concentrations (approximately 2, 25, and 40 µg/mL) was &lt;5% for each analyte. Accuracy studies for each analyte were compared using linear regression and demonstrated: slope = 1.0 ± 0.1; r2 ≥ 0.980; and y intercept 95% CI that included zero. Minimal ion suppression or enhancement was observed, and no significant carryover was observed up to 500 µg/mL of each analyte. Stability studies demonstrated significant loss in serum for each analyte at ambient and refrigerated temperatures (2–8 °C) and at −20 °C over days or weeks. In contrast, when stored at −80 °C, no significant loss was observed. Conclusions The LC-MS/MS assay showed acceptable performance characteristics for quantitation of β-lactams. With well-characterized stability, this assay can be used with residual specimens for pharmacokinetic modeling, which may lead to individualized dosing and improved patient care.
The Hidden Cost of Hemolyzed Blood Samples in the Emergency Department
Phelan, Michael , Ramos, Christopher, Walker, Laura , Richland, Gerald, Reineks, Edmunds, Ramos, Christopher

Mayo Clinic

The Journal of Applied Laboratory Medicine | April 5, 2021 | Volume: 6 | Issue: 6 | Pages: 1607-1610

10.1093/jalm/jfab035 | PMID 33997900 Get It

Abstract Background On average, patients with hemolyzed potassium samples spend about 1 h longer in the emergency department (ED), regardless of acuity level or disposition. We aimed to quantify the direct expenses associated with poor-quality preanalytic blood samples collected in the ED. Methods We created a simple table with a range of direct expenses (i.e., costs) and rates of hemolyzed sample draws, allowing for identification of potential high-level cost-of-care impact analysis. We included a range of costs informed by review of literature on the topic. Those costs range from $600 to $3000 per bed-hour. This amount was inflation adjusted from 1996 to 2020 (1.68 × [direct cost per visit] × [100 000 visits per year/365 days/24 h]). We provided a range of hemolysis incidence based on previously reported data. Results We showed that for an ED with 100 000 annual visits, a 40% draw rate for routine chemistries (including potassium), and a 10% hemolysis incidence, the direct cost impact of hemolysis waste is approximately $4 million/year as a result of the 1 h of added length of stay on average for a patient with a hemolyzed blood sample. This amount represents an annualized estimated cost of caring for a patient in the ED with an avoidable extended length of stay. Conclusions The financial burden of poor-quality blood samples can be estimated using cost per bed-hour and rate of sample failure. Similar methodology may identify additional QC issues with previously invisible financial implications.
Neuropathy Severity at the Time of Oxaliplatin Treatment Alteration in Patients with Colon Cancer (Alliance A151912)
Hertz, Daniel L. , Dockter, Travis , Satele, Daniel , Loprinzi, Charles L. , Hertz, Daniel L , Le‐Rademacher, Jennifer

Mayo Clinic

No container title available | April 5, 2021 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-300187/v1 Get It

Abstract Background: Clinical guidelines recommend altering chemotherapy treatment by decreasing, delaying, or discontinuing dosing in patients who are experiencing chemotherapy-induced peripheral neuropathy. There are few data available on the clinical use of treatment alteration including the severity of CIPN at the time of treatment alteration. Methods: This was a retrospective analysis of patients receiving oxaliplatin on the NCCTG N08CB trial. Neuropathy severity was assessed at each cycle by clinicians and patients. Patients were classified as 1) completed treatment without alteration, 2) dose reduction or delay due to neuropathy, 3) discontinuation due to neuropathy, or discontinuation for other toxicity (4), or another reason (5). Comparisons focused primarily on patients with alteration due to neuropathy (groups 2 and/or 3) compared with patients who completed treatment without alteration (group 1). Results: In 350 participants, 135 (39%) completed treatment without alteration, 70 (20%) had a dose reduction or delay due to neuropathy, and 35 (10%) discontinued early due to neuropathy. Clinician-assessed neuropathy severity was greater in patients at the time of dose reduction or delay compared with severity at the end of treatment in patients without alteration (p<0.0001). Patient-reported neuropathy severity at cycle 4 was worse in patients who had an alteration as compared with patients who completed treatment without alteration (p=0.017). Conclusions: Treatment alterations due to neuropathy are common in patients receiving oxaliplatin for colon cancer and are associated with clinician-assessed neuropathy severity. Rapid increases in patient-reported neuropathy severity indicate a potential need for monitoring and intervention.
Evaluation of Pancreatic Fibrosis Grading by Multiparametric Quantitative Magnetic Resonance Imaging
Liu, Chang , Shi, Yu , Lan, Gongyu, Xu, Youli , Yang, Fei , Shi, Yu

Mayo Clinic

Journal of Magnetic Resonance Imaging | April 5, 2021 | Volume: 54 | Issue: 5 | Pages: 1417-1429

10.1002/jmri.27626 | PMID 33819364 Get It

BackgroundEarly detection and grading of pancreatic fibrosis (PF) are important and challenging clinical goals.PurposeTo determine main pancreatic duct (MPD) diameter, pancreatic thickness, and grades of PF via magnetic resonance elastography (MRE), T1 mapping, and intravoxel incoherent motion diffusion‐weighted imaging (IVIM‐DWI), assessing respective diagnostic performances.Study TypeProspective.SubjectsHistopathologic and imaging records (MRE, T1 mapping, and IVIM‐DWI) generated by 144 patients between December 2018 and May 2020 were collected for analysis. Grades of PF were distributed as follows: F0, 82; F1, 22; F2, 22; and F3, 18.Field Strength/Sequence3 T pancreatic MRI, encompassing MRE, T1 mapping, and IVIM‐DWI.AssessmentIn all patients, T1 relaxation times, pancreatic stiffness values, IVIM‐DWI parameters, MPD diameter, and pancreatic thickness were measured.Statistical TestsReceiver operating characteristic (ROC) analysis served to assess imaging parameters useful in diagnosing PF. To identify relations between specific parameters and grades of PF, logistic regression analysis was invoked.ResultsBoth pancreatic stiffness (r = 0.754; P < 0.001) and T1 relaxation time (r = 0.433; P < 0.001) correlated significantly with PF (%). To determine PF grades ≥F1, a combined model (area under the curve [AUC] = 0.906) performed significantly better than pancreatic stiffness (AUC = 0.855; P < 0.001) or T1 relaxation time (AUC = 0.754; P < 0.001) alone. For PF grades ≥F2 or grade F3, both the combined model (≥F2: AUC = 0.910; F3: AUC = 0.939) and pancreatic stiffness (≥F2: AUC = 0.906; F3: AUC = 0.929) outperformed T1 relaxation time (≥F2: AUC = 0.768 [P = 0.005 and P = 0.004, respectively]; F3: AUC = 0.816 [both P < 0.005]). All IVIM‐DWI parameters generated AUC values <0.700.Data ConclusionA combination of MRE and T1 mapping seems promising in diagnosing various grades of PF, particularly at an early stage.Level of Evidence1Technical EfficacyStage 2
T-Cell Homeostatic Imbalance in Placentas From Women With Human Immunodeficiency Virus in the Absence of Vertical Transmission
Ikumi, Nadia M. , Pillay, Komala , Tilburgs, Tamara , Malaba, Thokozile R. , Dzanibe, Sonwabile , Enninga, Elizabeth Ann L. , Chakraborty, Rana , Myer, Landon , Jaspan, Heather B. , Gray, Clive M. , Enninga, Elizabeth Ann L , Gray, Clive M , Lamorde, Mohammed , Khoo, Saye

Mayo Clinic

The Journal of Infectious Diseases | April 5, 2021 | Volume: 224 | Issue: Supplement_6 | Pages: S670-S682

10.1093/infdis/jiab192 | PMID 33880544 Get It

Abstract Background Implementation of universal antiretroviral therapy (ART) has significantly lowered vertical transmission rates but has also increased numbers of human immunodeficiency virus (HIV)–exposed uninfected children, who remain vulnerable to morbid effects. In the current study, we investigated whether T-cell alterations in the placenta contribute to altered immune status in HIV-exposed uninfected. Methods We analyzed T cells from term placenta decidua and villous tissue and paired cord blood from pregnant women living with HIV (PWH) who initiated ART late in pregnancy (n = 21) with pregnant women not living with HIV (PWNH) (n = 9). Results Placentas from PWH showed inverted CD4/CD8 ratios and higher proportions of tissue resident CD8+ T cells in villous tissue relative to control placentas. CD8+ T cells in the fetal capillaries, which were of fetal origin, were positively correlated with maternal plasma viremia before ART initiation, implying that imbalanced T cells persisted throughout pregnancy. In addition, the expanded memory differentiation of CD8+ T cells was confined to the fetal placental compartment and cord blood but was not observed in the maternal decidua. Conclusions T-cell homeostatic imbalance in the blood circulation of PWH is reflected in the placenta. The placenta may be a causal link between HIV-induced maternal immune changes during gestation and altered immunity in newborn infants in the absence of vertical transmission.